L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy in newly-diagnosed glioblastoma: dose escalation of the phase I/II GLORIA trial

Abstract The chemokine CXCL12 promotes glioblastoma (GBM) recurrence after radiotherapy (RT) by facilitating vasculogenesis. Here we report outcomes of the dose-escalation part of GLORIA (NCT04121455), a phase I/II trial combining RT and the CXCL12-neutralizing aptamer olaptesed pegol (NOX-A12; 200/...

Full description

Bibliographic Details

Published in:	Nature Communications
Main Authors:	Frank A. Giordano, Julian P. Layer, Sonia Leonardelli, Lea L. Friker, Roberta Turiello, Dillon Corvino, Thomas Zeyen, Christina Schaub, Wolf Müller, Elena Sperk, Leonard Christopher Schmeel, Katharina Sahm, Christoph Oster, Sied Kebir, Peter Hambsch, Torsten Pietsch, Sotirios Bisdas, Michael Platten, Martin Glas, Clemens Seidel, Ulrich Herrlinger, Michael Hölzel
Format:	Article
Language:	English
Published:	Nature Portfolio 2024-05-01
Online Access:	https://doi.org/10.1038/s41467-024-48416-9